Index
Module 2 • Research Methods
Research Design, Biostatistics & Literature Evaluation
44%
Data Tables
Research Design, Biostatistics & Literature Evaluation
Julie E. Farrar ~3 min read Module 2 of 20
14
/ 32

Research Design, Biostatistics, and Literature Evaluation

F.

Pharmacokinetic and Pharmacodynamic trials

1

Studies designed to evaluate effects of unique disease states on clinically relevant pharmacokinetic and

pharmacodynamic parameters

2Trial designs can be prospective based on predefined sampling strategies or retrospective based in

routine clinical care laboratory samples (Clin Pharmacokinet 2015;7:783-95)

3

Large study size not needed to define properties in unique patient populations

4

Population based pharmacokinetic and pharamacodynamic studies can help define novel clinical dosing

strategies in unique patient populations

G.Noninferiority trial
1

Noninferiority trials seek to answer whether a competing treatment is no worse than the established

standard therapy (JAMA 2015;313:2371-2).

Example: Quetiapine is inferior to (worse than) haloperidol for hyperactive ICU delirium versus

quetiapine is no worse than haloperidol by X margin.

2Seeks to establish utility by showing similar effectiveness while improving safety or reducing treatment

burden (e.g., costs, inconvenience, labor)

3

Analytic approach to a noninferiority trial

What is an acceptable threshold for β€œnoninferiority”?

The FDA provides guidance for non-inferiority thresholds:

(a)Establish the smallest plausible benefit of the existing standard therapy.
(b)Insist on some preservation of the treatment effect of the standard therapy.
(c)The FDA recommends that 50% of the standard treatment effect be preserved when

evaluating mortality for thrombolytic trials.

ii.

Maximum allowable negative outcome

Threats to meaningful comparisons

Effect of standard treatment was not preserved. (e.g., heparin infusion does not achieve

therapeutic anticoagulation)

ii.

Intention-to-treat analysis: Suboptimal administration of the standard treatment

H.Study Design Considerations
1

Incidence versus prevalence

Incidence: Measures the occurrence of a disease (or event) over a time interval

Prevalence: Measures the occurrence of a disease (or event) at a fixed point in time

2Validity

Internal

Does the study design adequately test the hypothesis?

ii.

Are the study methods sound?

External

Is the study population representative of the clinical setting?

ii.

Are the study findings generalizable outside the study setting?

iii.

Can the study be replicated in clinical practice?

3

Bias: Systematic error leading to an estimate of association in the study population that varies from the

source population (Am J Health Syst Pharm 2008;65:2159-68)

Selection bias: Systematic selection of subjects that leads to an imbalance, or an advantage, in favor

of one cohort over the other

Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 13 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube